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INTRODUCTION
Electronic cigarettes, also called e-cigarettes are 
electronic nicotine delivery systems (ENDS). They can 
deliver vaporized liquid mainly containing nicotine 
and propylene glycol through the mouth into the 
lungs, mimicking the effects of conventional cigarette 
smoking1. Reportedly, the e-cigarette was invented 
by the Chinese pharmacist Hon Lik in 2003, and 
internationally patented in 20072. E-cigarettes have 
been commercially available in Europe and America 
since 2006 as a cigarette substitute3. E-cigarettes 
have always been advertised as healthy and popular 
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reported. 
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smoking cessation tools4. Reports have suggested 
that achieving abstinence by using e-cigarettes was 
comparable to nicotine replacement therapy (NRT), 
and e-cigarettes also appear to effectively decrease 
cigarette consumption5,6. This has resulted in a 
dramatic increase in the use of e-cigarettes worldwide. 
The estimated global value of e-cigarette sales was 
up to US$3.5 billion in 20157. A national large-scale 
survey from 28 EU member states reported that there 
were about 48.5 million e-cigarette users in 20168.
Increasingly teenagers are becoming addicted to 
e-cigarettes. Between 2016 and 2017, the proportion 
of e-cigarette users among those aged 11 to 16 years 
increased from 7% to 11%, respectively, across the 
UK9. The proportion of US high school teenagers 
who had tried e-cigarettes in the last month rose 
from 1.5% to 16.0% between 2011 and 2015, a more 
than 10-fold increase10. In 2019, it was estimated 
that among high school students in the US, 27.5% 
(95% CI: 25.3–29.7) were current e-cigarette users11. 
Worse still, many studies appear to report that use 
of e-cigarettes by young people increases the risk of 
subsequent cigarette smoking12, and that minors are 
an emerging new smoking population13. 
Concerns have been expressed about the safety of 
e-cigarettes. The US Food and Drug Administration 
(FDA) reported that e-cigarettes contained some 
toxic heavy metals and the concentration of heavy 
metals released by e-cigarettes was much higher 
than conventional cigarettes14. These were associated 
with the development of cancer15 and the occurrence 
of coronary events16. In light of the above, the 
FDA banned flavored e-cigarette sales in January 
2020, as flavored e-cigarettes had the most appeal 
to teenagers17. On 1 November 2019, China as the 
birthplace of e-cigarettes announced that the online 
purchase of e-cigarettes would be completely banned 
in China18. Previously, two randomized controlled 
trials (RCTs)5,6 indicated that e-cigarettes were 
potentially effective in smoking cessation among 
adult smokers. Published studies on cigarette smoking 
initiation associated with e-cigarette use among 
adolescents have been primary studies and there 
has been limited evidence synthesis. There are few 
evidence-based studies that have comprehensively 
evaluated the benefits and risks of e-cigarettes. 
Therefore, a rapid review was conducted to evaluate 
the effects of e-cigarettes on smoking cessation among 
smokers and the risks for smoking initiation among 
non-smoking adolescents, and their safety.
METHODS
Due to the urgent need to inform ongoing policy, 
a rapid review methodology was employed19. This 
type of simplified systematic review is helpful in 
providing a timely synthesis for decision makers. 
Streamlined methods are usually used in a rapid 
review, which usually includes limiting retrieval dates 
and databases19. This rapid review and meta-analysis 
are reported following Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA)20 
statement. A PRISMA statement with a checklist of 
items that should be included in reports of systematic 
reviews is included in the Supplementary file.
Eligibility criteria 
Systematic reviews based on RCTs or comparative 
observational studies (cohort and cross-sectional 
studies), parallel group RCTs and controlled cohort 
studies were included. The study population 
comprised adult smokers and non-smoking 
adolescents, who had no serious diseases or 
pregnancy. The study interventions were e-cigarettes. 
The controls referred to placebo e-cigarettes 
(without nicotine), NRT or no treatment. The 
primary outcomes were smoking cessation among 
smokers and smoking initiation among adolescents. 
The secondary outcome was occurrence of adverse 
events. Experimental studies and studies that failed 
to report the minimal required information were 
excluded. There was no need for approval from an 
ethics committee or agreement of participants in this 
study as data were extracted from publications that 
were in the public domain. 
Search strategy
Databases searched included PubMed, Web of 
Science, MEDLINE, EMBASE, the Cochrane library, 
China National Knowledge Infrastructure (CNKI), 
Chinese Scientific Journal Database (VIP), SinoMed 
and Wanfang, from January 2015 to June 2020. The 
reference lists included in the systematic reviews were 
also searched. A systematic search was also conducted 
in Clinical Trials.gov (www.clinicaltrials.gov) and 
Chinese Clinical Trial Registry (http://www.chictr.org.
cn/index.aspx). Search terms included: e-cigarettes, 
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electronic cigarettes, electronic nicotine delivery 
systems, vape, and vaping. An example of the PubMed 
search strategy is given in the Supplementary file. 
Study selection and data extraction 
After removing duplicates, two authors (SJZ and 
FLB) independently screened studies by title and 
abstract, according to the eligibility criteria. In 
the full text screening process, uncertainty and 
insufficient information was determined for eligibility 
through full texts. Disagreements were resolved by 
discussion or arbitrated by a methodologist (JPL). 
Reasons for excluding studies were recorded at 
this stage. After identification of studies, data were 
extracted independently by two authors (SJZ and 
FLB) and included: characteristics of study design 
(study type, setting, and funding); details of PICO 
(participants, interventions, comparisons, and 
outcomes); and follow-up and adjusted factors. Any 
disagreements were resolved by discussion or third-
party adjudication. 
Quality assessments
The methodological quality assessment of each 
included study was performed independently by two 
review authors (FLB and SJZ). Cochrane Risk of 
Bias tool (ROB)21 was employed to assess whether 
the risk of bias of RCTs was low, high or unclear 
according to its seven domains. A Measurement 
Tool to Assess Systematic Reviews (AMSTAR-2)22 
which has 16 items with 7 key items was employed 
to assess the quality of the included systematic 
reviews; the overall confidence for each review was 
assessed as high, moderate, low or critically low. The 
quality of cohort studies was assessed by Newcastle-
Ottawa Scale (NOS)23, which is composed of 8 items 
and includes three subscales: selection of studies, 
comparability of studies, and the ascertainment of 
exposure. The maximum score is 9 points and any 
study scoring >5 points was considered of moderate 
to high quality23. Grading of Recommendations 
Assessment, Development and Evaluation (GRADE)24 
was employed to assess the certainty of evidence 
from RCTs in five domains (risk of bias, directness, 
precision, consistencies, and publication bias).
Data synthesis
Qualitative and quantitative methods were adopted 
to synthesize the findings. The findings from 
systematic reviews were narratively described. Data 
are presented as risk ratios (RRs) or adjusted odds 
ratio (AORs) with 95% confidence intervals (CIs). 
Meta-analysis was performed by Stata version 14.0 
software when the trials had acceptable heterogeneity 
and similarities in clinical characteristics. The 
random effects model (REM) was utilized in the 
meta-analysis to consider potential sources of clinical 
heterogeneity. The I2 statistic was employed to assess 
statistical heterogeneity21. When p<0.10 and I2>50%, 
the heterogeneity may be considered as high21,25. To 
explain heterogeneity, we predefined the subgroup 
analysis by the frequency of e-cigarette use: intensive 
use (daily or regular use for at least one month) versus 
intermittent or irregular use. Sensitivity analysis was 
employed to test the robustness of the results when 
the primary outcomes were statistically different for 
the following three methodological domains: reported 
clear randomization concealment or not; placebo 
used or not; and reported lost to follow-up or not. 
Funnel plots were employed to detect the possibility 




Initially, 1620 records were retrieved and 926 
duplicates were removed. In all, 612 records were 
excluded by scanning the title and abstract due to 
irrelevant studies, protocols, clinical studies, case-
control studies or cross-sectional surveys, commentary 
of included studies, and studies that provided only 
abstracts. This left 82 remaining records, of these, 
47 studies were excluded through full-text screening 
due to ineligible study design, uncontrolled cohort 
studies or lack of cessation outcomes. Finally, 35 
studies were included after full-text screening. Of 
these studies, findings from 6 systematic reviews26-31 
were narratively described. The screening process is 
shown in Figure 1.
Description of studies
The characteristics of the included studies are shown 
in Tables 1 and 2. Included in the 35 studies identified 
were: 6 systematic reviews26-31, 5 RCTs32-36, and 24 
cohort studies37-60. These studies were classified into 
two categories based on the two primary outcome 
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measures. Nineteen studies26-30,32-45 examined the 
effects of e-cigarette use on smoking cessation, and 
the remaining 16 studies31,46-60 explored the causality 
between e-cigarette use and smoking initiation among 
teenagers. The study population included adult 
smokers and non-smoking adolescents and young 
adults. The definition of e-cigarette use was ‘current 
use’, ‘ever use’ or ‘past 30-day use’. In terms of the 
included 6 systematic reviews, 5 reviews26-30 focused 
on smoking cessation among adult smokers, and 
included either RCTs, cohort studies or cross-sectional 
studies. Another systematic review31 was based on 9 
cohort studies and explored the association between 
e-cigarette use and subsequent smoking initiation. 
The 5 RCTs32-36 involved data from 4025 adult 
smokers. The sample size ranged from 99 to 886. 
Three trials32, 34,35 compared the effect of e-cigarettes 
with NRT on smoking cessation. The other 2 
RCTs33,36 compared the effect of nicotine e-cigarettes 
with placebo or no treatment. A total of 24 cohort 
studies were identified. The sample size ranged from 
146 to 17318 with a total of 91985 participants. 
Nine studies37-45 focused on smoking cessation, of 
which, 4 studies37-39,42 overlapped with the included 
Figure 1. Flow chart of study selection 
RCTs: randomized controlled trials.
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Table 1. Characteristics of the included systematic reviews and randomized controlled trials
Study and Year Location Population/intervention Comparison Outcomes Included study types
Kalkhoran et al.26 
(2016) 
USA Adult smokers with nicotine 
EC use 
Non-EC users Probability of smoking 
cessation
15 cohort studies, 3 
cross-sectional studies 
and 2 clinical trials
El Dib et al.27 
(2017) 
Brazil Adult smokers with nicotine 
EC use
Placebo EC Probability of smoking 
cessation
3 RCTs and 9 prospective 
cohort studies
Hartmann-Boyce 
et al.28 (2016) 
UK Adult smokers with nicotine 
EC use  
Placebo EC Probability of smoking 
cessation




Canada Adult smokers with nicotine 
EC use
Placebo EC Probability of smoking 
cessation
3 RCTs and 2 
comparative 
observational studies
Rahman et al.30 
(2015)
Australia Adult smokers with nicotine 
EC use
Placebo EC Probability of smoking 
cessation
2 RCTs, 2 cohort 
studies and 2 cross-
sectional studies 
Soneji et al.31 
(2017) 
Lebanon Non-smoking teenagers with 
current or past 30-day nicotine 
EC use
Never or non-past 
30-day EC users 
Probability of cigarette 
smoking initiation
9 cohort studies
Hajek et al.32 
(2019)
UK Nicotine EC users (n=438) NRT (n=446) 1-year abstinence rate RCT
Tseng et al.33 
(2016) 
USA 4.5% nicotine EC users (n=50) Placebo EC (n=49) Abstinence rate at week 3 RCT
Lee et al.34 (2019) Korea Nicotine EC users (n=75) Nicotine gum (n=75) Abstinence rate at 9–24 
weeks
RCT
Li et al.35 (2019) UK Nicotine EC users (n=439) NRT (n=447) 1-year abstinence rate RCT
Halpern et al.36 
(2018)
USA Nicotine EC users (n=1199) No treatment 
(n=813)
6-month abstinence rate RCT
EC: electronic cigarette. NRT: nicotine replacement therapy. 
Table 2. Characteristics of the included cohort studies
Study and 
Year
Location Exposure Population Comparison Follow- 
up
Outcomes Adjusted factors Lost to 
follow-up 
(%)
Shi et al.37 
(2016)
USA Ever nicotine EC 
users (n=82)
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systematic reviews26-30. Another 15 cohort studies46-60 
focused on the association between e-cigarette use 
and subsequent smoking initiation among teenagers. 
Of these, six46,49-51,54,56 studies overlapped with the 
included systematic review31. The follow-up time 
varied from 6 months to 2 years.
Quality assessment
There were no26 or one28 non-critical weakness in 
two systematic reviews, and these were rated as 
high confidence according to AMSTAR-2. Three29-31 
were rated as low confidence due to the lack of a 
protocol and inadequate details of the included 
studies. One27 was of critically low confidence as it 
lacked a protocol and the lists of excluded studies. 
Details are shown in Table 3. In terms of the RCTs, 
the random sequence generation and allocation 
concealment for 3 RCTs32-34 were well described and 
were judged as having a low risk of bias. Blinding 
of the participants and personnel was only reported 
for one RCT33 and was rated as ‘low’ in the blinding 
domain. Apart from this, the risk of performance 
bias was rated as ‘high’ in the other 4 RCTs32,34-36, 
but the outcome assessment was blinded in these 4 
RCTs and were rated as having low risk of detection 
bias. Intention-to-treat analysis was conducted in 5 
RCTs32-36, and the attrition rate was <10%; all RCTs 
were assessed as having low risk of attrition bias. In 
terms of reporting bias, 3 RCTs34-36 were assessed 
as ‘low’ since the protocols were registered and 
the consistency between the outcomes described 
in protocol and actual outcomes in the results; the 
remaining 2 RCTs32,33 were assessed as ‘unclear’ due 
to lack of a registered protocol. The baseline data 
were comparable for 4 RCTs32,34-36, one35 was rated 
as ‘unclear’ due to the lack of baseline data. The risk 
of bias summary is shown in Figure 2. The quality of 
24 cohort studies scored between 5 and 7 according 
to the NOS grading due to the higher number of 
dropouts and self-reported outcomes. Overall, the 
quality was considered to be satisfactory. Details are 
shown in Table 4. 
Study and 
Year
Location Exposure Population Comparison Follow- 
up
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Effects of interventions 
Smoking cessation 
Findings from 5 systematic reviews
A Cochrane systematic review28 compared e-cigarettes 
with placebo e-cigarettes on smoking cessation, but 
only 2 RCTs5,6 were eligible for the meta-analysis. 
The abstinence rates for at least 6 months were 
4% (placebo group) and 9% (e-cigarette group), 
suggesting that e-cigarettes were more likely to favor 
cessation (RR=2.29; 95% CI: 1.05–4.96; low certainty; 
2 trials, n=662). This was consistent with 3 systematic 
reviews27,29,30. Another systematic review26 reported 
that the odds of cessation were 28% lower in the 
e-cigarette group than the non-use group (OR=0.72; 
95% CI: 0.57–0.91; 20 trials, n=355011). 
Findings from 5 RCTs
Five newly conducted RCTs32-36 reported the 
abstinence rate, with 180 of 2201 (8.2%) smokers 
achieving cessation in the e-cigarette group versus 
103 of 1824 (5.6%) in the control group, suggesting 
that e-cigarettes may be superior to NRT or placebo 
on smoking cessation (RR=1.55; 95% CI: 1.00–2.40; 
I2=57.6%; low certainty; 5 trials, n=4025) (Figure 
3, Table 5). However, the certainty of evidence was 
downgraded under GRADE assessment due to the 
small number of events (<300) and the inconsistency 
Table 3. AMSTAR-2 assessment of the included systematic reviews
Study and Year AMSTAR-2 Items Overall quality
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Kalkhoran et al.26 (2016) Y Y Y Y Y Y Y PY Y Y Y Y Y Y Y Y high
El Dib et al.27 (2017) Y N Y PY Y Y N Y Y Y PY Y Y Y Y Y critically low
Hartmann-Boyce et al.28 (2016) Y Y Y Y Y Y Y PY Y N Y Y Y Y Y Y high
Khoudigian et al.29 (2016) Y N Y Y Y Y Y PY Y Y Y Y Y Y Y Y low
Rahman et al.30 (2015) Y N Y Y Y Y Y N Y Y Y Y Y Y Y Y low
Soneji et al.31 (2017) Y N Y Y Y Y Y Y Y N Y Y Y Y Y Y low
Y: yes. N: no. PY: partial Y. CL: critically low. L: low. H: high. Item 1: Did the research questions and inclusion criteria for the review include the components of PICO?; Item 2: 
Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant 
deviations from the protocol?; Item 3: Did the review authors explain their selection of the study designs for inclusion in the review?; Item 4: Did the review authors use a 
comprehensive literature search strategy?; Item 5: Did the review authors perform study selection in duplicate?; Item 6: Did the review authors perform data extraction in 
duplicate?; Item 7: Did the review authors provide a list of excluded studies and justify the exclusions?; Item 8: Did the review authors describe the included studies in adequate 
detail?; Item 9: Did the review authors use a satisfactory technique for assessing the risk of bias (ROB) in individual studies that were included in the review?; Item 10: Did the 
review authors report on the sources of funding for the studies included in the review?; Item 11: If meta-analysis was performed, did the review authors use appropriate methods 
for statistical combination of results?; Item 12: If meta-analysis was performed, did the review authors assess the potential impact of ROB in individual studies on the results of 
the meta-analysis or other evidence synthesis?; Item 13: Did the review authors account for ROB in individual studies when interpreting/discussing the results of the review?; 
Item 14: Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the result of the review?; Item 15: If they performed 
quantitative synthesis, did the review authors carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review?; 








































































































































Hajek 2019        
Lee 2019        
Li 2019        
Tseng 2016        
Halpern 2018        
 
Figure 2. Risk of bias summary 
Figure 2. Risk of bias summary
Review Paper
Tobacco Induced Diseases 
Tob. Induc. Dis. 2021;19(January):4
https://doi.org/10.18332/tid/131624
9
Table 4. Newcastle-Ottawa Scale assessment of the included cohort studies
Study and Year Newcastle-Ottawa Scale
Selection Comparability Outcome Total score
Shi et al.37 (2016) 3 2 1 6
Biener et al.38 (2015) 3 2 1 6
Manzoli et al.39 (2015) 3 2 1 6
Zhuang et al.40 (2016)  2 2 1 5
Pasquereau et al.41 (2017) 2 2 1 5
Al-Delaimy et al.42 (2015)  3 2 1 6
Kalkhoran et al.43 (2019) 2 2 1 5
Jackson et al.44 (2019) 2 2 2 6
Kalkhoran et al.45 (2019) 2 2 1 5
Wills et al.46 (2016) 2 2 2 6
Aleyan et al.47 (2017) 2 2 3 7
Goldenson et al.48 (2017)  2 2 2 6
Leventhal et al. 49 (2015) 2 2 2 6
Primack et al.50 (2015) 3 2 1 6
Barrington-Trimis et al.51 (2016)  2 2 1 5
Barrington-Trimis et al.52 (2018) 1 2 2 5
Primack et al.53 (2018)  2 2 1 5
Unger et al.54 (2016) 2 2 2 6
Hammond et al.55 (2017)  2 2 2 6
Spindle et al.56 (2017) 2 2 2 6
Miech et al.57 (2017) 2 2 1 5
Chien et al.58 (2019) 2 2 2 6
Berry et al.59 (2019) 2 2 1 5
Mcmillen et al.60 (2019) 2 2 1 5
Figure 3. Meta-analysis of RCTs comparing e-cigarettes with NRT or placebo on smoking cessation 
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level (I2=57.6%). Details are shown in Table 5.
Findings from 9 cohort studies
Nine cohort studies37-45 reported the adjusted 
odds ratio (AOR) for cessation. The pooled results 
suggested that e-cigarettes were not associated with 
smoking cessation (AOR=1.16; 95% CI: 0.88–1.54; 
I2=69.0%; 9 trials, n=22220) (Figure 4). Subgroup 
analysis on the frequency of e-cigarette use suggested 
that intensive e-cigarette use was more effective in 
achieving cessation than non-use (AOR= 2.03; 95% 
CI: 1.35–3.05; I2=37.8%; 4 trials, n=1144) (Figure 4).
Smoking initiation
Findings from one systematic review
Only one systematic review31 based on cohort studies 
involving 17389 young people aged 14–30 years was 
identified. This review indicated that ever e-cigarette 
users were more likely to initiate cigarette smoking 
at follow-up than never users (23.2% vs 7.2%) 
(AOR=3.5; 95% CI: 2.38–5.16; I2=56.0%; 7 trials, 
n=8759). 
Table 5. Evidence summary of smoking cessation: e-cigarettes versus NRT or placebo





Study design Risk of 
bias
Inconsistency Indirectness Imprecision Other 
considerations
























a I2=57.6%. b Number of events <300. EC: electronic cigarette. NRT: nicotine replacement therapy. CI: confidence interval. RR: risk ratio. 
Figure 4. Meta-analysis of cohort studies comparing ever e-cigarette use with non-use on smoking cessation
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Findings from 15 cohort studies
Fifteen cohort studies46-60 were included. The pooled 
results suggested that ever e-cigarette users were 
more likely to initiate smoking than non-e-cigarette 
users (AOR=2.91; 95% CI: 2.61–3.23; I2=61.0%; 15 
trials, n=68943) (Supplementary file, Figure S1). 
Subgroup analysis on the frequency of e-cigarette 
use was not available, since only one trial52 reported 
the AOR of intensive and intermittent e-cigarette 
use. Sensitivity analysis was also unavailable due to 
insufficient data. The funnel plot based on the AORs 
of smoking initiation (Supplementary file, Figure S2) 
appeared to be asymmetrical, suggesting that there 
was potential publication bias.
Adverse events
Of the 35 included studies, adverse events were 
reported in 5 studies27-29,32,34. Two systematic 
reviews27,28 reported minor adverse short-term events 
related to e-cigarettes. These included irritation of 
the mouth and throat, cough and respiratory diseases, 
but long-term safety is still unknown. Two studies29,32 
reported that there was no statistical difference in 
adverse events between the e-cigarette group and 
control group. One RCT34 reported that adverse 
events were significantly lower in the e-cigarette 
group (6.7%) compared with the NRT group (17.3%); 
adverse events included oral pain, cough, headache, 
and nausea. No serious adverse events were reported 
in the included trials. 
DISCUSSION
Main findings
In the light of current policies on e-cigarettes in 
China and the US, it was timely to conduct a rapid 
review to comprehensively evaluate the benefits and 
risks of e-cigarettes. Thirty-five studies published 
from January 2015 to June 2020 were evaluated and 
included 6 systematic reviews, 24 cohort studies and 
5 RCTs. The study population included adult smokers 
with or without intention to cease smoking and 
non-cigarette smoking adolescents. Four systematic 
reviews27-30 indicated that e-cigarettes were superior 
to placebo for cigarette smoking cessation. Another 
systematic review26 reported that the odds of cessation 
were 28% lower in the e-cigarette group than the non-
use group. Five RCTs (two33,36 placebo or no treatment 
controlled and three32,34,35 NRT controlled) reported 
that the abstinence rate in the e-cigarette group was 
2.6% higher than that in the control group, suggesting 
that e-cigarettes may be more effective than NRT or 
placebo in achieving smoking cessation among adult 
smokers. However, this evidence was downgraded due 
to the small number of events and inconsistencies as 
assessed using GRADE. Nine cohort studies involving 
22220 adult smokers found that e-cigarettes were 
not superior to non-e-cigarette use for cessation. 
Subgroup analysis suggested that intensive e-cigarette 
use (daily or regular use for at least one month) may 
contribute to cessation, while intermittent or irregular 
use did not. In light of the limited number of RCTs 
and the findings from cohort studies on smoking 
cessation, we could not draw robust conclusions from 
current evidence. In terms of smoking initiation, one 
systematic review31 reported that ever or past 30-day 
e-cigarette use was more likely to initiate smoking 
among teenagers. Updated estimates (AORs) of 
15 cohort studies46-60 involving 68943 adolescents 
suggested that ever e-cigarette users were nearly 3 
times more likely than non-users to begin smoking 
cigarettes. However, the evidence was limited due to 
potential bias (self-reported outcomes, high dropouts 
and variations in the length of follow-up). No serious 
adverse events were reported in the included studies.
Comparisons with other studies
Previous systematic reviews26-30 have merely focused 
on the benefits of e-cigarettes for smoking cessation 
or the risks for smoking initiation31. Former systematic 
reviews were based on primary studies such as RCTs 
and cohort studies. We identified the latest systematic 
reviews, RCTs and cohort studies published in 
the last six years to provide comprehensive and 
rapid evidence for policy makers. This is the first 
rapid review to evaluate the benefits and risks of 
e-cigarettes, comprehensively. A newly published 
Cochrane systematic review61 found that nicotine 
e-cigarettes were superior to placebo e-cigarettes or 
NRT for smoking cessation. This was consistent with 
the findings from 5 newly conducted RCTs32-36 in 
this rapid review. In addition, this review conducted 
a subgroup analysis based on the frequency of 
e-cigarette use.
Implications 
For the study design, future studies should consider 
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the frequency of e-cigarette use, the concentration of 
nicotine in e-cigarettes and the type of e-cigarettes, 
since the quitting or initiating smoking effects of 
e-cigarette use could be potentially affected by 
those factors. E-cigarette products change very 
rapidly, especially the Juul type e-cigarettes, which 
use nicotine salt and can deliver a higher dose of 
nicotine62. Juul is the most popular e-cigarette in the 
US63. Therefore, it is essential to study new products 
in the future in terms of their effect on quitting 
or initiating cigarettes. The definition of smoking 
cessation or smoking initiation needs to be clarified, 
the current standards suggest that the duration is 
for at least 30 days cessation or smoking initiation at 
follow-up. Likewise, the effects of electronic cigarettes 
on smoking cessation among smokers with long-term 
or short-term smoking may vary. Hence, different 
smoking durations among smokers should be well 
reported and stratified in future studies. In terms 
of outcomes, objective measurements of smoking 
initiation rather than self-reported measurements 
are warranted. Cotinine as a biomarker64 of smoke 
exposure can be used to predict smoking initiation 
among adolescents. Additionally, dropouts should 
be minimized as much as possible in future cohort 
studies. Last but not least, the long-term safety of 
e-cigarette use should also be a future focus. For 
policy makers, appropriate e-cigarette use may be 
potentially effective in smoking cessation for adult 
smokers. However, e-cigarette use in adolescents 
was potentially associated with subsequent smoking 
initiation, and therefore the sale of e-cigarettes to 
minors should be banned completely worldwide. 
Strengths and limitations
Rapid review methodology was employed to provide 
timely evidence on e-cigarette use due to the urgent 
need to inform ongoing government policies. This is 
the first rapid review to evaluate the benefits and risks 
of e-cigarettes, comprehensively. The latest eligible 
systematic reviews, RCTs and cohort studies were 
all identified in order to provide a comprehensive 
evaluation on e-cigarette use. However, there are 
several limitations. First, similar to other rapid 
reviews, the search time was limited from January 
2015 to June 2020, and some evidence may have been 
missed. The results for smoking initiation were at risk 
of publication bias. Second, though the evidence from 
5 RCTs suggested that e-cigarettes were superior to 
NRT or placebo for smoking cessation, the certainty 
of evidence was downgraded due to imprecision and 
inconsistency. Additionally, evidence from 9 cohort 
studies suggested that ever e-cigarette use was not 
associated with smoking cessation. Thus, the smoking 
cessation effect of e-cigarettes still could not be 
determined based on current evidence. 
CONCLUSIONS 
Low certainty evidence suggests that e-cigarettes 
appear to be potentially effective in smoking cessation 
for adult smokers. However, this beneficial effect 
needs to be further confirmed in large sample, 
well designed and fully reported trials. The use of 
e-cigarettes in adolescents may be associated with 
subsequent smoking initiation. No serious adverse 
events were reported in the included studies, however, 
the long-term safety of e-cigarettes should also be a 
future focus. 
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